Mitotic slippage: an old tale with a new twist

Area of Science:

• Oncology
• Cell Biology
• Genetics

Background:

• Anti-mitotic drugs are a cornerstone of cancer therapy but suffer from unpredictable patient responses and acquired drug resistance.
• A major resistance mechanism involves cancer cells exiting mitotic arrest (mitotic slippage), leading to survival and often chromosomal instability (CIN) and aneuploidy.

Purpose of the Study:

• To review mechanisms of cell fate determination during perturbed mitosis and their impact on anti-mitotic therapy efficacy.
• To highlight the role of Centrosomal Protein (55 KDa) (CEP55) in protecting aneuploid cells from death.
• To discuss targeting CEP55 as a novel therapeutic strategy.

Main Methods:

• Review of existing literature on mitotic slippage, chromosomal instability, and anti-mitotic drug resistance.
• Emphasis on recent laboratory findings regarding CEP55 function in aneuploid cells.
• Discussion of the therapeutic potential of targeting CEP55 in combination with microtubule inhibitors.

Main Results:

• Cancer cells with chromosomal instability (CIN) and aneuploidy often develop resistance to anti-mitotic drugs through mitotic slippage.
• Centrosomal Protein (55 KDa) (CEP55) plays a crucial role in protecting aneuploid cells from undergoing apoptosis.
• Targeting CEP55 shows promise in sensitizing resistant cancer cells to existing therapies.

Conclusions:

• Understanding cell fate mechanisms during perturbed mitosis is critical for improving cancer therapy.
• CEP55 is a key mediator protecting aneuploid cells and represents a potential therapeutic target.
• Targeting CEP55 could enhance the efficacy of anti-mitotic drugs, leading to better patient outcomes in cancers with chromosomal instability.